Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing's sarcoma cells.

Max-Johann SturmJulián Andrés Henao-RestrepoSabine BeckerHans ProquittéJames F BeckJürgen Sonnemann

Published in: Journal of cancer research and clinical oncology (2023)

Our study reveals that combined targeting of ATR and RNR was effective against Ewing's sarcoma in vitro and thus rationalises an in vivo exploration into the potential of combining ATR and RNR inhibitors as a new strategy for the treatment of this challenging disease.

Keyphrases

dna damage response
induced apoptosis
cancer therapy
cell cycle arrest
oxidative stress
cell death
risk assessment
drug delivery
dna damage